Compare VanEck Gold Miners ETF (GDX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? VanEck Gold Miners ETF trades at $84.15 (market cap $26.33B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: VanEck Gold Miners ETF is far larger — about 3.5× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 77 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GDX | SYRE | |
|---|---|---|
Market Cap | $26.33B | $7.52B |
Volume | 15,141,546 | 1,441,031 |
52-Week High | $115.84 | $108.92 |
52-Week Low | $68.28 | $22.18 |
Typical Hold Time | 77 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $87.24, down 1.46% on the day, with technical indicators showing a neutral to bearish bias amid mixed signals from moving averages and oscillators. The ETF's fundamental metrics are not provided in the snapshot, but recent news highlights ongoing institutional repositioning and comparisons between gold miners and physical gold. Support and resistance levels are tightly clustered around the current price, suggesting near-term consolidation.
The outlook for GDX hinges on gold price trends and interest rate movements, with potential upside from inflation hedging demand but risks from institutional selling and metal volatility. Investors face a balanced risk-reward scenario given neutral sentiment and lack of clear directional catalysts.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
